Cellect Biotechnology Ltd. Warrants to Purchase ADR (1 WT and $7.50 to purchase 1 ADS)
APOPW
NASDAQ Capital Market0.09
USD
+0.00
- -
CIK
0001671502
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
-12.22
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- United States of America
- IPO Date
- Jul 29, 2016
- CIK
- 0001671502
- Similar Companies
- Business
- Cellect Biotechnology Ltd. (NASDAQ:APOP; Warrants: APOPW), a biotechnology company, develops and commercializes stem cell selection technologies to improve the safety and efficacy of regenerative medicine and cell therapies, including its proprietary ApoGraft platform that functionally selects stem cells from any tissue to reduce graft-versus-host disease risk in bone marrow transplantations and ApoTainer, a shelf-stable kit for allogeneic hematopoietic stem cell transplantation procedures in hematological malignancies; the company also offers FasL-based reagents for scalable stem cell enrichment supporting clinical and research applications in immuno-oncology and gene therapy. Founded in 2011 and headquartered in Kfar Saba, Israel, Cellect targets pharmaceutical companies, research institutions, hospitals, and clinicians globally with operations centered in Israel and collaborations extending to Europe and the United States. In October 2021, Cellect completed a reverse merger acquisition by Quoin Pharmaceuticals, Inc., under which it renamed to Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) and shifted primary focus to rare disease therapeutics while divesting its stem cell subsidiary Cellect Biotherapeutics Ltd. to EnCellX, Inc. for continued ApoGraft development including U.S. clinical trials; the APOPW warrants remain outstanding linked to the legacy entity now operating as Quoin, which in 2025 reported ongoing QRX003 pivotal trials for Netherton Syndrome, secured $16.45 million in funding via warrant issuances, and announced positive pediatric clinical data alongside financial results showing $6.4 million in assets as of September 30, 2025.
Head to Head Survey: CELLECT BIOTECH/S (NASDAQ:APOP) versus Cryolife (NASDAQ:CRY)
CELLECT BIOTECH/S (NASDAQ:APOP) vs. Irhythm Technologies (NASDAQ:IRTC) Financial Survey
Financial Review: CELLECT BIOTECH/S (NASDAQ:APOP) vs. LeMaitre Vascular (NASDAQ:LMAT)